Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Inc (NYSE: TFX) is a global medical technology leader developing devices that enhance patient care across surgical, interventional, and critical care settings. This news hub provides investors and healthcare professionals with timely updates on TFX's clinical advancements, regulatory milestones, and strategic initiatives.
Access authoritative reporting on product innovations like the UroLift system, vascular access solutions, and anesthesia devices that demonstrate Teleflex's commitment to evidence-based medicine. Our curated news collection covers essential developments including quarterly earnings, FDA clearances, partnership announcements, and clinical trial outcomes.
Key updates focus on Teleflex's core therapeutic areas: minimally invasive surgical tools, critical care devices, and urology solutions. Stay informed about technologies improving procedural safety and healthcare economics through verified press releases and objective analysis.
Bookmark this page for consolidated access to Teleflex's latest progress in medical device innovation, financial performance data, and market expansion efforts. Regularly updated to serve as your primary resource for understanding TFX's role in advancing global medical standards.
Teleflex announced positive results from four studies on the UroLift System for treating benign prostatic hyperplasia (BPH) at the ICS 2020 Annual Meeting. These studies confirm the safety and efficacy of the UroLift System, demonstrating significant symptom improvement for men suffering from BPH. With over 40% of men over 50 affected by BPH, the treatment is becoming a preferred option. Key findings included high catheter independence rates (86%-87%) and notable symptom relief, reinforcing the UroLift System as a minimally invasive solution that maintains sexual function.
Teleflex Incorporated (NYSE: TFX) announced that Liam Kelly, Chairman, President, and CEO, will speak at the Stephens Investment Conference on November 16, 2020, at 1:00 p.m. ET. A live audio webcast of the presentation, along with the slide presentation, will be accessible on the investor section of Teleflex's website. Teleflex is dedicated to enhancing healthcare through innovative medical technologies across various fields, including vascular access, anesthesia, and respiratory care.
Teleflex Incorporated (NYSE: TFX) announced a quarterly cash dividend of $0.34 per share of common stock. This dividend will be paid on December 15, 2020 to shareholders recorded as of November 15, 2020. Teleflex is committed to providing medical technologies that enhance the health and quality of life of patients. The company focuses on innovation to meet clinical needs across diverse fields including vascular access, urology, and emergency medicine. For more details, visit teleflex.com.
Teleflex reported third quarter 2020 revenues of $628.3 million, a decline of 3.1% year-over-year. GAAP diluted EPS was $2.46, down 49.3% from $4.85 in the previous year. Adjusted EPS fell 6.7% to $2.77. Revenue was adversely affected by the COVID-19 pandemic, with an estimated $78 million impact, contributing to a 12% revenue loss. Despite these challenges, growth was noted in the Interventional Urology sector and Vascular Access products. The company announced an acquisition of Z-Medica, LLC, expected to enhance earnings per share in 2021.
Teleflex Incorporated (NYSE: TFX) has entered a definitive agreement to acquire Z-Medica, LLC for $500 million plus potential performance bonuses of $25 million. The acquisition, aimed at enhancing Teleflex's portfolio in hemostatic products, is expected to close in Q4 2020, pending regulatory approvals. Z-Medica's innovative products, including QuikClot and Combat Gauze, are poised to boost Teleflex's revenue by $60-$70 million in fiscal 2021 and enhance earnings per share. The deal aligns with Teleflex's strategy to invest in high-growth medical technologies.
Teleflex (NYSE: TFX) expands its UroLift portfolio with the new UroLift Advanced Tissue Control (ATC) System, aimed at enhancing treatment for benign prostatic hyperplasia (BPH). Cleared by the FDA in June 2020, the UroLift ATC System offers advancements in treating complex prostate anatomies, allowing urologists to more effectively manage obstructive median lobes and large lateral lobes. Early feedback from urologists indicates satisfaction with its usability and effectiveness. The UroLift System has shown significant positive outcomes in patient symptoms and quality of life, establishing its credibility in the market.
Teleflex Incorporated has launched the Arrow® ErgoPack® Complete CVC System, marking a significant update in more than a decade. This system is designed after extensive research with vascular access professionals and includes features such as the Arrow GlideWheel™ Advancer for improved control and a kink-resistant nitinol guidewire. With a focus on reducing CLABSI, the system complies with major health guidelines. Teleflex's Arrowg+ard Blue Plus® CVC is the only full-spectrum antimicrobial catheter addressing key pathogens linked to CLABSI, which causes up to 28,000 deaths annually in the U.S.
Teleflex Incorporated (NYSE: TFX) is set to release its third-quarter 2020 financial results before the market opens on October 29, 2020. An investor conference call will follow at 8:00 a.m. ET. Interested parties can access the live audio webcast on the company’s website. The replay of the call will be available from November 29, 2020, until November 3, 2020. Teleflex is dedicated to improving health through medical technologies across various fields, including vascular access and surgical care.
Teleflex Incorporated (NYSE: TFX) has received 510(k) clearance from the U.S. FDA to extend the indications for use of the Arrow® EZ-IO® Intraosseous Vascular Access System. This device can now be utilized for up to 48 hours when traditional intravenous access is challenging. The expansion is particularly vital for patients requiring long-term access during emergencies.
According to Corporate Vice President Michelle Fox, this advancement aims to enhance patient care during times of resource constraints.
